<unk>  has been used as medical therapy in gallstone disease (cholelithiasis) and for biliary sludge.<unk>  helps reduce the cholesterol saturation of bile and leads to gradual dissolution of cholesterol-rich gallstones.<unk>  may be given after bariatric surgery to prevent cholelithiasis, which commonly occurs due to the rapid weight loss producing biliary cholesterol oversaturation and also biliary dyskinesia secondary hormonal changes. Primary biliary cholangitis<unk>  is used as therapy in primary biliary cholangitis (PBC; previously known as primary biliary cirrhosis) where it can produce an improvement in biomarkers. Meta-analyses have borne out conflicting results on the mortality benefit. However analyses that exclude trials of short duration (i.e. < 2 years) have demonstrated a survival benefit and are generally considered more clinically relevant. A Cochrane systematic review in 2012 found no significant benefit in reducing mortality, the rate of liver transplantation, pruritus or fatigue.<unk> diol and obeticholic acid are FDA-approved for the treatment of primary biliary cholangitis. Primary sclerosing cholangitis<unk>  use is associated with improved serum liver tests that do not always correlate with improved liver disease status. WHO Drug Information advises against its use in primary sclerosing cholangitis in unapproved doses beyond 13–15 mg/kg/day.<unk>  in a dose of 28-30mg/kg/day increases risk of death and need for liver transplant by 2.3 folds among those with primary sclerosing cholangitis, despite decrease in liver enzymes. Intrahepatic cholestasis of pregnancy<unk>  has been used for intrahepatic cholestasis of pregnancy.<unk>  lessens itching in the mother and may reduce the number of preterm births. Effects on fetal distress and other adverse outcomes are unlikely to be great. Cholestasis<unk>  use is not licensed in children, as its safety and effectiveness have not been established. Evidence is accumulating that<unk>  is ineffective, unsafe and its use is associated with significant risk of morbidity and mortality in neonatal hepatitis and neonatal cholestasis. Other conditions<unk>  has been suggested to be an adequate treatment of bile reflux gastritis. In cystic fibrosis there is insufficient evidence to justify routine use of<unk> , especially as there is a lack of available data for long-term outcomes such as death or need for liver transplantation.<unk>  has also been in effective in non-alcoholic fatty liver disease, in liver bile duct-paucity syndromes. It is contraindicated in obstruction of biliary tracts such as biliary atresia. It's not effective in liver allograft rejection, and in Graft-versus-host disease involving the liver.
Ursodeoxycholic acid
Chenodeoxycholic acid
Obeticholic acid
Rifaximin
Calcifediol
Sucralfate
Omega-3 carboxylic acids
Colestyramine